• CARAVAGGIO Expands DOAC Pool in Cancer-related VTE

    1 month ago - By Medscape

    Randomized but open-label data show apixaban was noninferior to dalteparin for efficacy but with less major bleeding, including problematic GI bleeds.
    Medscape Medical News
    Read more ...

     

  • PRONOMOS: Rivaroxaban Bests Enoxaparin for VTE Prophylaxis

    1 month ago - By Medscape

    New trial results show rivaroxaban was not only noninferior but superior to enoxaparin in reducing venous thromboembolism after nonmajor orthopedic surgery.
    Medscape Medical News
    Read more ...

     

  • Apixaban noninferior to dalteparin for cancer-related VTE treatment

    1 month ago - By Healio

    Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without increasing major bleeding risk, according to results from the CARAVAGGIO trial presented at the virtual American College of Cardiology Scientific Session.
    “The findings of CARAVAGGIO expand the proportion of patients with cancer-associated thrombosis who are eligible for the treatment with the oral direct anticoagulants, including patients with gastrointestinal cancer,” Giancarlo Agnelli, MD, professor of internal medicine and chairman of the postgraduate program in emergency
    Read more ...